Jacek Kordiak

Jacek Kordiak

Auto-generated profile, based on publicly available information

Jacek Kordiak

Department of Thoracic, General and Oncological Surgery, Medical University of Lodz, 90-151 Lodz, Poland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
JKJacek Kordiak
Jacek Kordiak
Filip BielecFilip Bielec
Filip Bielec
SJSławomir Jabłoński
Sławomir Jabłoński
Dorota Pastuszak-LewandoskaDorota Pastuszak-Lewandoska
Dorota Pastuszak-Lewandoska
Lung cancer is one of the most common neoplasms globally, with about 2.2 million new cases and 1.8 million deaths annually. Although the most important factor in reducing lung cancer risk is lifestyle change, most patients favour the use of supplements, for example, rather than quitting smoking or following a healthy diet. To better understand the efficacy of such interventions, a systematic review was performed of data from randomized controlled trials concerning the influence of beta-carotene supplementation on lung cancer risk in subjects with no lung cancer before the intervention. The search corpus comprised a number of databases and eight studies involving 167,141 participants, published by November 2021. The findings indicate that beta-carotene supplementation was associated with an increased risk of lung cancer (RR = 1.16, 95% CI = 1.06–1.26). This effect was even more noticeable among smokers and asbestos workers (RR = 1.21, 95% CI = 1.08–1.35) and non-medics (RR = 1.18, 95% CI = 1.07–1.29). A meta-regression found no relationship between the beta-carotene supplementation dose and the size of the negative effect associated with lung cancer risk. Our findings indicate that beta-carotene supplementation has no effect on lung cancer risk. Moreover, when used as the primary chemoprevention, beta-carotene may, in fact, increase the risk of lung cancer.

1 December 2009 in Lung Cancer
Verified
Journal Article
Closed access
MBMagdalena Bieniasz
Magdalena Bieniasz
Katarzyna OszajcaKatarzyna Oszajca
Katarzyna Oszajca
MEMak Eusebio
Mak Eusebio
JKJacek Kordiak
Jacek Kordiak
JBJacek Bartkowiak
Jacek Bartkowiak
JSJanusz Szemraj
Janusz Szemraj

9 July 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AAAdam Antczak
Adam Antczak
Dorota Pastuszak-LewandoskaDorota Pastuszak-Lewandoska
Dorota Pastuszak-Lewandoska
PGPaweł Górski
Paweł Górski
DDDaria Domańska
Daria Domańska
MMMonika Migdalska-Sęk
Monika Migdalska-Sęk
EBEwa Brzeziańska-Lasota
Ewa Brzeziańska-Lasota
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a potent immunoregulatory molecule that downregulates T-cell activation and thus influences the antitumor immune response. CTLA-4 polymorphisms are associated with various cancers, and CTLA-4 mRNA/protein increased expression is found in several tumor types. However, most of the studies are based on peripheral blood mononuclear cells, and much less is known about the relationship between CTLA-4 expression, especially gene expression, and its polymorphic variants in cancer tissue. In our study we assessed the distribution of CTLA-4 two polymorphisms (+49A/G and −318C/T), using TaqMan probes (rs231775 and rs5742909, resp.), andCTLA-4gene expression in real-time PCR assay in non-small-cell lung cancer (NSCLC) tissue samples. The increasedCTLA-4expression was observed in the majority of NSCLC patients, and it was significantly correlated with TT genotype (−318C/T) and with tumor size (T2 versus T3 + T4). The presence of G allele and GG genotype in cancer tissue (+49A/G) was significantly associated with the increased NSCLC risk. Additionally, we compared genotype distributions in the corresponding tumor and blood samples and found statistically significant differences. The shift from one genotype in the blood to another in the tumor may confirm the complexity of gene functionality in cancer tissue.

27 October 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
JKJacek Kordiak
Jacek Kordiak
JSJanusz Szemraj
Janusz Szemraj
IGIzabela Grabska-Kobylecka
Izabela Grabska-Kobylecka
PBPiotr Bialasiewicz
Piotr Bialasiewicz
MBMarcin Braun
Marcin Braun
DNDariusz Nowak
Dariusz Nowak
Purpose Mutated KRAS oncogene in exhaled breath condensate (EBC) can be a genetic marker of non-small cell lung cancer (NSCLC). However, a possibility of inhomogeneous distribution in cancer tissue and intratumor heterogeneity of KRAS mutation may decrease its significance. We investigated a status of KRAS point mutation and its sequence at codon 12 in 51 NSCLC patients after tumor resection. The comparison of KRAS mutation status between EBC–DNA and cancer tissue was performed in 19 cases. Methods Five cancer tissue samples from disparate tumor regions and one from normal lung were harvested at surgery. EBC was collected for DNA analysis the previous day. KRAS point mutations at codon 12 were detected using mutant-enriched PCR technique and pyrosequenced. Results Forty-six cancers revealed concordance of KRAS mutation status: 27 contained mutated KRAS and 19 had only wild KRAS. Five NSCLCs revealed inhomogeneous distribution of KRAS mutation. Two different mutations were found in 14 NSCLCs and the most frequent one was G12D and G12V (n = 8). No mutated KRAS was found in normal lung. The concordance ratios of KRAS sequence in codon 12 between EBC–DNA and cancer were 18/19 for NSCLC patients and 11/12 for KRAS mutation positive NSCLC. Conclusions Intratumor heterogeneity and inhomogeneous distribution of KRAS point mutation in codon 12 in cancer tissue can occur in NSCLCs. There was a high accordance between KRAS mutation status in EBC–DNA and cancer tissue in NSCLC patients what suggests usefulness of monitoring KRAS mutation in EBC–DNA as a biomarker of NSCLC.

13 August 2018 in Molecular Diagnosis & Therapy
Verified
Journal Article
Open access
PDF file
Dorota Pastuszak-LewandoskaDorota Pastuszak-Lewandoska
Dorota Pastuszak-Lewandoska
DDDaria Domańska-Senderowska
Daria Domańska-Senderowska
AAAdam Antczak
Adam Antczak
JKJacek Kordiak
Jacek Kordiak
PGPaweł Górski
Paweł Górski
EBEwa Brzeziańska-Lasota
Ewa Brzeziańska-Lasota
The interleukin (IL)-4/IL-13/signal transducer and activator of transcription (STAT) 6 signaling pathway and the SOCS3 gene, one of its main regulators, constitute an important link between the inflammation process in the epithelial cells and inflammatory-related tumorigenesis. The present study is the first to evaluate IL-4, IL-13, STAT6, and SOCS3 mRNA expression in non-small cell lung carcinoma (NSCLC) histopathological subtypes.

1 January 2014
Verified
Book Chapter
Closed access
PDF file
DPD. Pastuszak-Lewandoska
D. Pastuszak-Lewandoska
KCKarolina Henryka Czarnecka-Chrebelska
Karolina Henryka Czarnecka-Chrebelska
MMM. Migdalska-Sęk
M. Migdalska-Sęk
ENE. Nawrot
E. Nawrot
DDD. Domańska
D. Domańska
EBEwa Brzeziańska-Lasota
Ewa Brzeziańska-Lasota